JP4302980B2 - Ｇａｂａ受容体リガンドとしてのイミダゾ−トリアジン誘導体 - Google Patents

Ｇａｂａ受容体リガンドとしてのイミダゾ−トリアジン誘導体 Download PDF

Info

Publication number
JP4302980B2
JP4302980B2 JP2002541100A JP2002541100A JP4302980B2 JP 4302980 B2 JP4302980 B2 JP 4302980B2 JP 2002541100 A JP2002541100 A JP 2002541100A JP 2002541100 A JP2002541100 A JP 2002541100A JP 4302980 B2 JP4302980 B2 JP 4302980B2
Authority
JP
Japan
Prior art keywords
fluoro
trifluoromethylimidazo
phenyl
triazine
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002541100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004513171A5 (enExample
JP2004513171A (ja
Inventor
ベツタテイ，ミケーラ
ブラートン，ピーター
カーリング，ウイリアム・ロバート
チエインバーズ，マーク・スチユワート
ハレツト，デイビツド・ジエイムズ
ジエニングス，アンドリユー
ルイス，リチヤード・トーマス
ラツセル，マイケル・ジエフリー・ニール
ストリート，レスリー・ジヨージフ
セケレシユ，ヘレン・ジエーン
バン・ニール，モニク・ボデイル
Original Assignee
メルク シャープ エンド ドーム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0027562A external-priority patent/GB0027562D0/en
Priority claimed from GBGB0117277.4A external-priority patent/GB0117277D0/en
Application filed by メルク シャープ エンド ドーム リミテッド filed Critical メルク シャープ エンド ドーム リミテッド
Publication of JP2004513171A publication Critical patent/JP2004513171A/ja
Publication of JP2004513171A5 publication Critical patent/JP2004513171A5/ja
Application granted granted Critical
Publication of JP4302980B2 publication Critical patent/JP4302980B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002541100A 2000-11-10 2001-11-08 Ｇａｂａ受容体リガンドとしてのイミダゾ−トリアジン誘導体 Expired - Fee Related JP4302980B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0027562A GB0027562D0 (en) 2000-11-10 2000-11-10 Therapeutic agents
GBGB0117277.4A GB0117277D0 (en) 2001-07-16 2001-07-16 Therapeutic agents
PCT/GB2001/004948 WO2002038568A1 (en) 2000-11-10 2001-11-08 Imidazo-triazine derivatives as ligands for gaba receptors

Publications (3)

Publication Number Publication Date
JP2004513171A JP2004513171A (ja) 2004-04-30
JP2004513171A5 JP2004513171A5 (enExample) 2005-12-22
JP4302980B2 true JP4302980B2 (ja) 2009-07-29

Family

ID=26245271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002541100A Expired - Fee Related JP4302980B2 (ja) 2000-11-10 2001-11-08 Ｇａｂａ受容体リガンドとしてのイミダゾ−トリアジン誘導体

Country Status (9)

Country Link
US (1) US6936608B2 (enExample)
EP (1) EP1343788B1 (enExample)
JP (1) JP4302980B2 (enExample)
AT (1) ATE310740T1 (enExample)
AU (2) AU1253002A (enExample)
CA (1) CA2427779A1 (enExample)
DE (1) DE60115282T2 (enExample)
ES (1) ES2251518T3 (enExample)
WO (1) WO2002038568A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0212048D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
JP2006507237A (ja) * 2002-08-13 2006-03-02 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体に対するリガンドとしてのフェニルピリダジン誘導体
AU2003278377A1 (en) * 2002-11-06 2004-06-07 Merck Sharp And Dohme Limited Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic
JPWO2005019238A1 (ja) 2003-08-22 2006-10-19 明治製菓株式会社 新規アザライド及びアザラクタム誘導体とその製造法
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1966158B1 (en) 2005-12-20 2012-08-08 AstraZeneca AB Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis
US7465795B2 (en) 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
PL2497470T3 (pl) 2006-11-22 2016-04-29 Incyte Holdings Corp Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2456311A4 (en) * 2009-07-24 2013-01-23 Concert Pharmaceuticals Inc SUBSTITUTED IMIDASOTRIAZINES
CN102030770B (zh) * 2009-09-25 2012-10-31 北京大学 一种芳香硼酸酯化合物的制备方法
EP2468726B1 (en) * 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
CN102898315B (zh) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 3-乙炔基-4-氟苯胺的制备方法
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
CN104177304A (zh) * 2013-05-28 2014-12-03 海洋王照明科技股份有限公司 双极性蓝光磷光主体材料及其制备方法和有机电致发光器件
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
LT3105226T (lt) 2014-02-13 2019-11-11 Incyte Corp Ciklopropilaminai, kaip lsd1 inhibitoriai
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CA2951497C (en) 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
CA3012791C (en) 2016-01-27 2024-01-23 Universitat Zurich Use of gabaa receptor modulators for treatment of itch
US10927099B2 (en) 2017-03-21 2021-02-23 Mississippi State University Unsymmetric CCC-NHC pincer metal complexes and methods of use thereof
TW202012402A (zh) * 2018-04-18 2020-04-01 美商紐羅塞克醫療公司 Gabaa正向異位性調節劑化合物、其製造方法及用途
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
AU2020371635A1 (en) * 2019-10-22 2022-06-09 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
US20230020036A1 (en) * 2019-10-23 2023-01-19 Neurocycle Therapeutics, Inc. Treatment of epileptic conditions with gabaa receptor modulators
KR102537615B1 (ko) * 2020-02-25 2023-05-30 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CN120865250A (zh) 2022-02-25 2025-10-31 上海赛默罗生物科技有限公司 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN117069725A (zh) 2022-05-10 2023-11-17 上海赛默罗生物科技有限公司 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1581125B1 (de) 1966-03-26 1970-08-27 Maierform Trust Reg Bug fuer Verdraengungsschiffe
US3422194A (en) * 1967-08-15 1969-01-14 Smithkline Corp The treatment of depression with imidazo(1,2-b)-as-triazines and compositions thereof
DE60025604T2 (de) 1999-06-22 2006-07-27 Neurosearch A/S Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
GB0117277D0 (en) * 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
US6936608B2 (en) 2005-08-30
AU1253002A (en) 2002-05-21
EP1343788A1 (en) 2003-09-17
ATE310740T1 (de) 2005-12-15
US20040023964A1 (en) 2004-02-05
AU2002212530B2 (en) 2006-08-17
DE60115282T2 (de) 2006-08-10
WO2002038568A1 (en) 2002-05-16
DE60115282D1 (de) 2005-12-29
CA2427779A1 (en) 2002-05-16
ES2251518T3 (es) 2006-05-01
EP1343788B1 (en) 2005-11-23
JP2004513171A (ja) 2004-04-30

Similar Documents

Publication Publication Date Title
JP4302980B2 (ja) Ｇａｂａ受容体リガンドとしてのイミダゾ−トリアジン誘導体
US7005431B2 (en) Imidazo-triazine derivatives as ligands for gaba receptors
JP4216905B2 (ja) Ｇａｂａ受容体に対するリガンドとしての置換トリアゾローピリダジン誘導体
US7279580B2 (en) Imidazo-pyridine derivatives as ligands for GABA receptors
AU2002212530A1 (en) Imidazo-triazine derivatives as ligands for GABA receptors
EP1383768B1 (en) Imidazo-pyrimidine derivatives as ligands for gaba receptors
CA2461426C (en) Imidazo-pyrimidine derivatives as ligands for gaba receptors
US6900215B2 (en) Imidazo-pyrimidine derivatives as ligands for gaba receptors
AU2002241139A1 (en) Imidazo-pyrimidine derivatives as ligands for GABA receptors
EP1511748B1 (en) 8-fluorimidazo(1,2-a)pyridine derivatives as ligands for gaba receptors
JP2004501109A (ja) Ｇａｂａ受容体に対するリガンドとしての３−フェニル−イミダゾ−ピリミジン誘導体
AU2002241138A1 (en) Imidazo-pyrimidine derivatives as ligands for GABA receptors
EP1532120B1 (en) Phenylpyridazine derivatives as ligands for gaba receptors
US20040171633A1 (en) (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses
US20040192692A1 (en) 5-Phenyl[1,2,4]triazines as ligands for GABA-A alpha2/alpha3 receptors for treating anxiety or depression
US7381725B2 (en) Pyridazine derivatives as ligands for GABA receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080916

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090407

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090423

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120501

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees